Discover

ELAN
Elanco Animal Health Incorporated
24.09
700 x undefined
300 x undefined
bid
ask
-
0.52
2.11%
500 @ 07:09 AM
24.30 +0.21 (0.87%)
Ytd6.45%
1y66.94%
24.05
day range
25.20
13.39
52 week range
27.72
Open24.36Prev Close24.61Low24.05High25.20Mkt Cap12.03B
Vol3.40MAvg Vol5.78MEPS-0.50P/EN/AForward P/E20.27
Beta1.70Short Ratio5.46Inst. Own111.33%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0650-d Avg23.08200-d Avg22.851yr Est29.86
Earning
DateForEstimateReportedSurprisesurprise %
2026-05-062026-030.340.40.0617.65%
2026-02-242025-120.11N/AN/AN/A
2026-02-242025-120.110.130.0218.18%
2025-11-052025-090.13N/AN/AN/A
2025-11-052025-090.130.190.0646.15%
2025-08-072025-060.20.260.0630.00%
Upgrade / Downgrade
DateFirmActionFromTo
2026-06-18TD CowenUpgradeBuyBuy
2026-05-07CitigroupUpgradeBuyBuy
2026-05-07JP MorganUpgradeOverweightOverweight
2026-04-15CitigroupUpgradeBuy
2026-02-25Morgan StanleyUpgradeEqual-WeightEqual-Weight
2026-02-25KeybancUpgradeOverweightOverweight
Profile
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Insider Holder
DateNameRelationQuantityDescription
2026-02-26BETTINGTON TIMOTHY JOfficer147.96KStock Award(Grant)
2026-02-26CABRAL RAMIRO MARTINOfficer290.37KStock Award(Grant)
2026-03-31DE BRABANDER ELLENOfficer280.82KStock Award(Grant)
2026-05-20HOOVER R DAVIDDirector277.37KStock Award(Grant)
2026-02-26KINARD DAVID SOfficer217.70KStock Award(Grant)
2026-05-20KURZIUS LAWRENCE ERIKDirector148.65KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Dodge & Cox Inc.68.94M1.66B13.80%
2026-03-30FMR, LLC50.93M1.23B10.20%
2026-03-30Blackrock Inc.47.62M1.15B9.54%
2026-03-30Primecap Management Company45.84M1.10B9.18%
2026-03-30T. Rowe Price Investment Management, Inc.34.64M834.71M6.93%
2026-03-30Dimensional Fund Advisors LP24.53M591.10M4.91%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-03-30Dodge & Cox Funds-Dodge & Cox Stock Fund45.27M1.09B9.06%
2026-03-30VANGUARD CHESTER FUNDS-Vanguard PRIMECAP Fund17.84M429.90M3.57%
2026-05-30iShares Trust-iShares Core S&P Mid-Cap ETF16.86M406.22M3.37%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund15.82M381.37M3.17%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund11.46M276.27M2.30%
2026-03-30VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund10.25M247.11M2.05%